title: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
abstract: Therapeutic immunization with autologous monocyte-derived dendritic cells (DCs) loaded with heat-inactivated autologous human immunodeficiency virus type 1 (HIV-1) in 12 patients with chronic HIV-1 infection who were receiving highly active antiretroviral therapy (HAART) was feasible, safe, and well tolerated. Virus was obtained during an initial interruption of HAART (hereafter, "stop 1") so that DCs could be pulsed. After immunization and a second interruption of HAART (hereafter, "stop 2"), set-point plasma viral load (PVL; 24 weeks after stop 2) decreased > or =0.5 log(10) copies/mL relative to baseline PVL in 4 of 12 patients. We observed a significant lengthening in mean doubling time of PVL rebound and significant decreases in the area under the curve and the mean peak of PVL rebound after stop 2, compared with those after stop 1. This response was associated with changes in HIV-1-specific CD4(+) lymphoproliferative and CD8(+) T cell responses. These changes were not observed in a group of nonimmunized control patients.
authors.affiliation: Infectious Diseases Unit, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Hospital Clínic, University of Barcelona, Spain. fgarcia@clinic.ub.es
authors.forename: Felipe
authors.initials: F
authors.lastname: García
authors.forename: Merylene
authors.initials: M
authors.lastname: Lejeune
authors.forename: Nuria
authors.initials: N
authors.lastname: Climent
authors.forename: Cristina
authors.initials: C
authors.lastname: Gil
authors.forename: José
authors.initials: J
authors.lastname: Alcamí
authors.forename: Vanessa
authors.initials: V
authors.lastname: Morente
authors.forename: Llucia
authors.initials: L
authors.lastname: Alós
authors.forename: Alba
authors.initials: A
authors.lastname: Ruiz
authors.forename: Javier
authors.initials: J
authors.lastname: Setoain
authors.forename: Emilio
authors.initials: E
authors.lastname: Fumero
authors.forename: Pedro
authors.initials: P
authors.lastname: Castro
authors.forename: Anna
authors.initials: A
authors.lastname: López
authors.forename: Anna
authors.initials: A
authors.lastname: Cruceta
authors.forename: Carlos
authors.initials: C
authors.lastname: Piera
authors.forename: Eric
authors.initials: E
authors.lastname: Florence
authors.forename: Arturo
authors.initials: A
authors.lastname: Pereira
authors.forename: Agnes
authors.initials: A
authors.lastname: Libois
authors.forename: Nuria
authors.initials: N
authors.lastname: González
authors.forename: Meritxell
authors.initials: M
authors.lastname: Guilá
authors.forename: Miguel
authors.initials: M
authors.lastname: Caballero
authors.forename: Francisco
authors.initials: F
authors.lastname: Lomeña
authors.forename: Joan
authors.initials: J
authors.lastname: Joseph
authors.forename: José M
authors.initials: JM
authors.lastname: Miró
authors.forename: Tomás
authors.initials: T
authors.lastname: Pumarola
authors.forename: Montserrat
authors.initials: M
authors.lastname: Plana
authors.forename: José M
authors.initials: JM
authors.lastname: Gatell
authors.forename: Teresa
authors.initials: T
authors.lastname: Gallart
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000502:physiology; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology; D003713:Dendritic Cells / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D015164:Vaccines, Inactivated / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D015164:Vaccines, Inactivated